Formulary Update May 2022

The following changes to the <u>Adult Medicines Formulary</u> have been agreed during the ADTC or sub-committee meetings since March 2022. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed here

Deletions	Indication	Adult Medicines Formu	Adult Medicines Formulary entry/ rationale	
Glibenclamide	Antidiabetic	6.1.2.1	Tablets currently not available in	
			the UK; oral suspension not	
			recommended by SMC	
Halofantrin	Antimalarial	5.4.1	Currently no product launched	
			in UK	
Evolve HA	Dry eyes	11.8.1	Formulary appeal	
Hylo-Forte	Dry eyes	11.8.1	Formulary appeal	
Chlorhexidine	Bladder instillation	7.4.4	Formulary section review	
Dimethyl sulfoxide	Bladder instillation	7.4.4	Formulary section review	
Glycin	Bladder instillation	7.4.4	Formulary section review	
Noxythioloin	Bladder instillation	7.4.4	Formulary section review	
Additions	Indication	Adult Medicines Formulary entry/ rationale		
Mexiletine	Cardiac arrhythmias	2.3.2	Formulary appeal	
Eyeaze 0.4% (hyaluronic acid)	Dry eyes	11.8.1	Formulary appeal	
Cystistat (Sodium hyaluronate)	Bladder instillations	7.4.4	Formulary section review	
iAluRil (hyaluronic acid, choindroitin	Bladder instillation	7.4.4	Formulary section review	
sulphate)				
Changes in preferred medicines or	New preferred medicines or brand	Adult Medicines Formulary entry / rationale		
brand				
Other changes	Changes made	Adult Medicines Formulary entry/ rationale		